Addressing Alcohol Use in HIV-Infected Persons

Alcohol use is common among persons with HIV infection and is associated with worse HIV treatment outcomes. Patients with hazardous levels of use are less likely to be receiving antiretroviral therapy, to be adherent to therapy, and to achieve virologic suppression. Screening, intervention, and referral to care for alcohol use disorder is an integral part of clinical care for individuals with HIV infection. Brief screening procedures can identify level of risk and determine whether patients require brief alcohol intervention or should be considered for behavioral therapy and pharmacologic treatment. Identification of concurrent mental health disorders is an important aspect of treating alcohol use disorders in HIV infection and other clinical settings. This article summarizes a presentation by Geetanjali Chander, MD, MPH, at the 14th Annual Clinical Conference for the Ryan White HIV/AIDS Program held in Tampa, Florida, in June 2011. The Clinical Conference is sponsored by the IAS–USA under the Health Resources and Services Administration (HRSA) contract number HHSH250200900010C.

Introduction

Alcohol use is common in HIV-infected persons, with data from national samples indicating that 50% report any alcohol use and that the rate of hazardous use is twice that in the general population. Alcohol use worsens common comorbid conditions in HIV-infected persons, including hepatitis C virus (HCV) and hepatitis B virus (HBV) infections, diabetes, and hypertension. It also increases HIV risk behaviors, including having unprotected sex, multiple sex partners, and high-risk injection behaviors. Alcohol use is associated with worse HIV treatment outcomes, and mortality.

Hazardous alcohol use is defined as more than 7 drinks per week or more than 3 drinks per occasion for women of any age and for men older than 65 years. In men aged 65 years or younger, hazardous use is defined as more than 14 drinks per week or more than 4 per occasion. Data from a study of approximately 1700 patients at the Johns Hopkins HIV Clinic showed that hazardous alcohol use (in the absence of drug use) was associated with reduced likelihood of being on or being adherent to antiretroviral therapy and reduced likelihood of achieving virologic suppression (Table 1).

Screening for Alcohol Use

In HIV clinical settings, all patients presenting for care should be screened for alcohol use. If screening is negative at baseline, it should be repeated at least annually; if positive, it should be repeated at every visit. Screening is relatively easy and straightforward. The National Institute on Alcohol Abuse and Alcoholism recommends asking a single, validated, screening question, “How often in the last year have you had 4 or more drinks?” (for women) or “5 or more drinks?” (for men). If such consumption has occurred on more than 1 occasion, follow-up questions should be used to identify quantity and frequency of drinking, eg, “How many standard drinks do you have on a typical drinking day?” and “How many days per week do you usually drink?” Instruments for follow-up include the AUDIT-C (Alcohol Use Disorders Test—Consumption) and the CAGE (Cut down, Annoyed, Guilty, Eye-opener) questionnaire. Some clues that may prompt screening for alcohol use include changes in medication or appointment adherence, symptoms of depression or anxiety, changes in laboratory measures (eg, an increase in aspartate aminotransferase [AST] on liver function testing [LFT]), changes in blood pressure or diabetes control, or a new sexually transmitted infection.

It is important to note that a “standard” drink is any that contains 14

<table>
<thead>
<tr>
<th>Drug Use</th>
<th>Alcohol Use</th>
<th>Antiretroviral Therapyb</th>
<th>Adherencec</th>
<th>Virologic Suppressiond</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>No</td>
<td>1.0 (Reference)</td>
<td>1.0 (Reference)</td>
<td>1.0 (Reference)</td>
</tr>
<tr>
<td></td>
<td>Moderate</td>
<td>1.14 (0.95-1.37)</td>
<td>0.77 (0.62-0.98)</td>
<td>1.00 (0.84-1.20)</td>
</tr>
<tr>
<td></td>
<td>Hazardous</td>
<td>0.57 (0.42-0.77)</td>
<td>0.36 (0.25-0.53)</td>
<td>0.72 (0.52-0.99)</td>
</tr>
<tr>
<td>Yes</td>
<td>No</td>
<td>0.54 (0.43-0.68)</td>
<td>0.50 (0.37-0.68)</td>
<td>0.60 (0.46-0.78)</td>
</tr>
<tr>
<td></td>
<td>Moderate</td>
<td>0.68 (0.54-0.88)</td>
<td>0.40 (0.30-0.54)</td>
<td>0.64 (0.50-0.82)</td>
</tr>
<tr>
<td></td>
<td>Hazardous</td>
<td>0.40 (0.29-0.57)</td>
<td>0.32 (0.20-0.51)</td>
<td>0.50 (0.32-0.76)</td>
</tr>
</tbody>
</table>

Adapted from Chander et al.6

Adjusted for age, sex, race, CD4+ cell count nadir, and days enrolled in study

Sample includes individuals either receiving antiretroviral therapy or with CD4+ cell count ≤ 350/µL

Adjusted for age, sex, race, CD4+ cell count nadir, and years receiving antiretroviral therapy (days)

See page 135 for information on CME credit for this article.
grams of alcohol, and that an alcoholic drink includes beer, wine, and liquor. Thus, a standard drink is 12 fluid ounces of regular beer, 8 ounces to 9 ounces of malt liquor, 1 glass of table wine, or 1.5 ounces (1 shot) of 80-proof liquor. Patients may say they have had 2 drinks or “two 40s,” referring to two 40-ounce bottles of beer or malt liquor—actually equivalent to approximately 7 standard drinks. They may describe a pint or “a fifth” of vodka as a single drink, actually equivalent to 11 and 17 standard drinks, respectively.

**Drinking Definitions**

Alcohol use covers a spectrum from “none” or “never exceeds limit” to “at-risk,” where there are not yet major consequences to drinking, through “harmful,” “severe” (dependent), and “chronic dependent” (Figure 1). At-risk alcohol use includes hazardous alcohol use, defined as more than 7 standard drinks per week in women and more than 14 standard drinks per week in men, and binge drinking, defined as drinking to a blood alcohol content of 0.08% or greater (roughly 5 approximately 7 standard drinks. They may describe a pint or “a fifth” of vodka as a single drink, actually equivalent to 11 and 17 standard drinks, respectively.

Any 3 of the following within the prior 12 months: (1) Tolerance, defined as (a) need for increased amounts of alcohol to achieve intoxication or desired effect, or (b) markedly diminished effect with continued use of same amount. (2) Withdrawal, manifested by (a) tremors, sweating, insomnia, etc, and (b) use of the same (or closely related) substance to avoid or relieve such symptoms. (3) Using the substance in larger amounts or over a longer period than intended. (4) Persistent desire or unsuccessful efforts to cut down or control use. (5) Great expenditure of time in activities necessary to obtain or use the substance or recover from its effects. (6) Withdrawal from or reduced participation in social, occupational, or recreational activities because of substance use. (7) Continued use despite recurrent or persistent physical or psychological problems caused or exacerbated by the substance use. Chronic dependence differs from severe use by the presence of more factors among the criteria for dependence, and is usually exhibited by patients who cycle in and out of treatment programs.

Patients who do not drink or never exceed limits should be screened annually. Those in the at-risk or harmful segment of the spectrum should receive a brief intervention, and those in the harmful to chronic dependent segment are candidates for behavioral therapy and pharmacologic treatment. Consider a patient who describes her alcohol use as consisting of 4 drinks every Friday night out with friends, with no other alcohol use during the week, no interference with work, no drinking and driving, and no other signs of alcohol abuse or dependence. This patient is actually a hazardous, or “at-risk,” drinker, and should receive a brief alcohol intervention.

**Brief Alcohol Interventions**

A brief alcohol intervention is a short, directed interaction that provides personalized feedback based on alcohol use and related problems (eg, elevated LFTs, depression, increased interpersonal conflicts, poor HIV medication adherence). It offers specific drinking reduction strategies, such as setting goals for safer drinking, alternatives to drinking, and management of risky moods or situations. The brief intervention is a low-cost, cost-effective treatment that promotes reductions in drinking in non–alcohol-dependent persons, as well as facilitates treatment referral in dependent persons.

Components of the brief intervention include the following:

- **Ask**: Screen for alcohol use in all patients.
- **Assess**: Assess for risk and consequences, including family history; legal, medical, and social consequences; and alcohol dependence. Assess for readiness to change.
- **Advise**: Provide feedback on drinking and medical, social, and behavioral consequences, and make recommendations for cutting down or quitting alcohol use.
- **Arrange for follow-up**.

Assessing patients’ readiness for change can assist in productively advising them on their alcohol use. Readiness to change can be assessed using a question such as: “On a scale of 1 to 10, with 1 being not ready at all and 10 being ready, how ready are you to change your alcohol use?” Patients’ confidence in their ability to change can be assessed by asking, “On a scale of 1 to 10, how confident are you that you can change your alcohol use?” If the patient is ambivalent...
about changing, a discussion should be initiated about the positive and negative aspects of alcohol use or the “pros” and “cons.” A useful technique is to “develop discrepancy”—to have the patient examine alcohol use within the context of their other values and goals and to encourage them to consider how their drinking may conflict with these values and goals. Patients who are ready to change should be helped with goal formulation, guided to resources, and given referrals. Follow-up is imperative for both the ready and the ambivalent.

The basic content of advice for those with drinking problems is as follows:

- **Cut down**: For the hazardous drinker—one with no major consequences from drinking—recommend reducing alcohol use to nonhazardous levels.

- **Cut down or abstain**: For those with harmful alcohol use—e.g., no alcohol dependence, but some consequences from drinking—recommend either reduction to nonhazardous levels of alcohol use or abstinence.

- **Abstain**: For those who (a) are alcohol dependent, (b) are pregnant, (c) have HCV infection or other medical conditions in which alcohol use is not recommended, (d) are on medications that interact with alcohol, (e) have blackouts, or (f) are unsuccessful at cutting back on use—recommend abstinence from alcohol.

**Treatment for Alcohol-Dependent Patients**

Alcohol-dependent patients should be referred to treatment programs. HIV clinicians should be familiar with local resources for substance-abuse treatment and related psychiatric care, including inpatient or residential treatment, outpatient treatment, and support groups such as Alcoholics Anonymous. In addition, clinicians should assess for potential withdrawal symptoms.

Clinicians should also consider the use of pharmacotherapy in dependent individuals. Medications are available that target neurotransmitters involved in the reinforcing effects of alcohol use. Pharmacotherapy for alcohol dependence in combination with behavioral counseling can reduce relapse and help maintain abstinence.

HIV clinics offer a number of advantages as a site for alcohol pharmacotherapy. These clinics are involved in long-term patient care, are generally characterized by integration of a variety of specialty services (eg, psychiatric and ob/gyn services), and have access to funding for prescription medications. Further, many HIV clinics use intensive case management models that promote outreach to and retention of patients who are often challenging to treat. However, currently there are no data on pharmacotherapy for alcohol dependence in patients with HIV infection, although a number of trials are under way. Further, pharmacotherapy for dependence has shown only modest efficacy in clinical trials.

Thus far, US Food and Drug Administration (FDA)-approved treatments for alcohol dependence are naltrexone (oral and injectable forms), acamprosate, and disulfiram.

**Naltrexone.** Naltrexone blocks opioid receptors and thus lessens the positive reinforcing effects of alcohol consumption. Naltrexone treatment decreases craving, reduces the number of heavy drinking days, and reduces the frequency of relapse to heavy drinking. A Cochrane systematic review of 50 randomized controlled trials of oral naltrexone involving 7795 patients found a 17% reduction in risk of returning to heavy drinking, a 4% reduction in drinking days, and improvement in levels of gamma-glutamyl transferase (GGT, a marker for liver damage).11

For oral naltrexone treatment, the patient must be opioid-free for 7 days to 10 days and it is recommended that patients be alcohol-free for at least 5 days to 7 days. The starting dose is 12.5 mg/d to 25 mg/d, increases to 50 mg/d, and treatment is for a minimum of 2 months. Naltrexone is classified by the FDA as pregnancy category C and should not be used during pregnancy. Patients should have LFTs monitored regularly, as naltrexone is associated with hepatitis. Other adverse effects consist mainly of nausea, headache, dizziness, nervousness, insomnia, abdominal pain, and cramping.12

Extended-release naltrexone administered via intramuscular (IM) injection is given at a dose of 380 mg monthly, with abstinence required before the start of treatment. Similar to oral naltrexone, individuals should be opioid free before initiating IM naltrexone. Adverse effects include decreased appetite, dizziness, fatigue, vomiting, and injection site reactions including cellulitis, induration, abscess, and necrosis. A randomized, placebo-controlled trial in more than 400 patients showed that monthly IM naltrexone was associated with a 25% reduction in the rate of heavy drinking days.13

**Acamprosate.** Acamprosate affects the glutamate and gamma-aminobutyric acid (GABA) neurotransmitter systems. It has shown moderate efficacy in European trials that has not been replicated in US trials. A Cochrane meta-analysis of 24 randomized, controlled trials involving 6915 patients showed that acamprosate was associated with a statistically significant reduction in risk for any drinking and increased cumulative abstinence duration.14 A dosage of 666 mg is taken 3 times daily, and alcohol abstinence is required before starting treatment. The drug is categorized as pregnancy category C. Dose adjustment is required with renal insufficiency and is contraindicated in individuals with a creatinine clearance of less than 30 mL/min.

**Disulfiram.** Disulfiram inhibits aldehyde dehydrogenase, increasing levels of acetaldehyde and causing flushing, tachycardia, sweating, nausea, vomiting, and headache if the patient drinks alcohol. Close monitoring of LFTs is necessary, as disulfiram is associated with hepatitis. Neuropathy is also an adverse effect associated with disulfiram. The drug is metabolized by cytochrome P450 3A isoenzymes,
Brief Mental Health Screening Tools for Patients With Alcohol Use

Two-Question Screen for Depression

Over the last 2 weeks, how often have you been bothered by the following problems?

• Have you experienced little interest or pleasure in doing things?
• Have you felt down, depressed, or hopeless?

Generalized Anxiety Disorder 7-Item Scale

How often during the past 2 weeks have you felt bothered by:

• Feeling nervous, anxious, or on edge? ___
• Not being able to stop or control worrying? ___
• Worrying too much about different things? ___
• Trouble relaxing? ___
• Being so restless that it is hard to sit still? ___
• Becoming easily annoyed or irritable ___
• Feeling afraid as if something awful might happen? ___

Total ___

Scoring

0 = not at all 2 = more than half the days 1 = several days 3 = nearly every day

Total score ≥ 10 should prompt further evaluation.

Concurrent Substance Use and Mental Health Disorders

Identification and treatment of concurrent mental health disorders is crucial to managing substance use among persons with HIV. Among HIV-infected persons, 15% have been found to have concurrent psychiatric symptoms and either drug dependence or heavy drinking. A study in HIV-infected veterans showed that hazardous drinkers were 2.55 times more likely to meet criteria for depression and binge drinkers were 2.14 times more likely to meet the criteria. Mental health disorders may worsen the negative health and social consequences of drug and alcohol misuse and interfere with treatment of substance use disorders. Substance use among individuals with mental illness can lead to worsening symptoms, increased hospitalizations, and decreased medication or appointment adherence. Concomitant substance-use disorder and mental illness is also associated with a greater financial burden to society. Mental health screening tools that can be used to assess patients with positive screening for alcohol use include a 2-question screen for depression and a 7-item screening instrument for generalized anxiety (see sidebar).

Patients with a triple diagnosis of HIV infection, substance use disorder, and mental health disorder face a number of barriers to care because they must navigate numerous health-care settings if they are to receive treatment for all disorders. Integrated care in the HIV clinic can greatly facilitate treatment for these individuals. As stated by Soto and colleagues, “Integrated HIV care combines HIV primary care with mental health and substance abuse services into a single coordinated treatment program that simultaneously, rather than in parallel or sequential fashion, addresses the clinical complexities associated with having multiple needs and conditions.”

An optimal integrated care system provides such ancillary services as housing and transportation assistance and case management, in addition to providing centralized care for medical, substance use, and mental health issues. Perhaps the most important components of such a system are communication and shared decision making among collaborators involved in patient care.

Lecture presented by Dr Chander in June 2011. First draft prepared from transcripts by Matthew Stenger. Reviewed and edited by Dr Chander in October 2011.

Financial Disclosure: Dr Chander has no relevant financial affiliations to disclose.

References

6. Smith PC, Schmidt SM, Allensworth-Davies D, Saiz R. Primary care valida-


*Dr Chander’s recommended curricula, review articles, and websites.
**Conflicts of Interest and Financial Disclosures**

IAS–USA policy requires that the IAS–USA resolve any real or apparent conflict of interest that may influence the development, content, or delivery of its educational activity prior to the activity’s being delivered to learners. The IAS–USA has several mechanisms for resolving conflicts of interest in educational activities. If the conflict of interest cannot be resolved through these mechanisms, the party will be removed from the activity.

Dr Chander has no relevant financial affiliations to disclose.

Dr Richman has been a consultant to Biota, Bristol-Myers Squibb, CHIMERx, Gen-Probe Inc, Gilead Sciences, Inc, Idenix Pharmaceuticals, Inc, Johnson & Johnson, Merck & Co, Inc, and Monogram Biosciences, Inc; received research grants or contracts from Merck & Co, Inc; and holds stock options in CHIMERx and Idenix Pharmaceuticals, Inc; and Johnson & Johnson, Merck & Co, Inc, and Monogram Biosciences, Inc; receives research grants or contracts from Merck & Co, Inc; and holds stock options in CHIMERx and Idenix Pharmaceuticals, Inc.

Dr Benson has no relevant financial affiliations to disclose.

Disclosure information for other IAS–USA contributors (but not in control of this activity content) can be found at www.iasusa.org.

**Learning Objectives**

Upon completion of this activity, learners will be able to recognize the impact alcohol misuse has on HIV disease outcomes, screen for hazardous alcohol use, and describe pharmacotherapy and brief interventions for alcohol-dependent patients.

**Accreditation Statement**

The IAS–USA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The IAS–USA designates this journal-based CME activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Intended Audience**

This activity is intended for physicians involved in the care of patients infected with HIV or other viruses. It is also relevant to nurse practitioners, physician assistants, nurses, and other health professionals who provide care for people with viral diseases.

**Posttest Questions**

**Check the box next to the single best answer to each of the questions below. To earn CME credit, you must receive a passing score of 80% or more correct.**

1. Which statement about alcohol consumption and HIV-infected patients is correct?
   - [ ] A. Hazardous alcohol use is associated with increased likelihood of being on antiretroviral therapy
   - [ ] B. The rate of hazardous alcohol use in HIV-infected patients is twice that in the general population
   - [ ] C. Patients presenting for care who screen positive for alcohol use should be screened annually thereafter

2. Which criterion is included in the definition of “at-risk” alcohol use?
   - [ ] A. More than 7 standard drinks per week in women of any age or men older than 65 years
   - [ ] B. More than 7 standard drinks per week in women of any age or men of any age
   - [ ] C. More than 5 drinks per occasion in women of any age or men older than 65 years

3. A female patient regularly consumes 4 drinks every Friday night, but has no other alcohol use during the week and her drinking has no impact on work or interpersonal relationships. How would you classify her drinking pattern?
   - [ ] A. A moderate drinking pattern that is safe to maintain
   - [ ] B. An “at-risk” drinking pattern
   - [ ] C. Alcohol dependence
   - [ ] D. Not enough information to diagnose

4. Which statement about oral naltrexone treatment is correct?
   - [ ] A. The starting dose is 10 mg/d and titrates upward to 50 mg/d, with treatment continued for a maximum of 2 months
   - [ ] B. Patients must be opioid-free for 7 to 10 days and alcohol-free for 5 to 7 days before treatment initiation
   - [ ] C. Oral naltrexone is safe to use during pregnancy

5. Chronic alcohol dependence is differentiated from alcohol dependence (ie, severe alcohol use) by:
   - [ ] A. The presence of withdrawal symptoms (tremors, sweating, insomnia, etc) on discontinuation of alcohol use
   - [ ] B. Unsuccessful efforts to cut down on alcohol use
   - [ ] C. The presence of more alcohol dependence factors than are found in severe alcohol use
   - [ ] D. Failure to complete an alcohol treatment program

This CME activity is offered from December 1, 2011, to December 1, 2012. Participants who receive a passing score on the posttest and submit the registration and evaluation forms are eligible to receive credit. Physicians (MDs, DOs, and international equivalents) may receive CME credit for completing this activity. Nonphysician health care practitioners will receive a certificate of attendance.
To receive CME credit, please complete the posttest, participant information, and evaluation forms and return all to the IAS–USA.

**Participant Information**

Number of CME credits I am claiming (maximum 1.5): __

<table>
<thead>
<tr>
<th>First Name</th>
<th>MI</th>
<th>Last Name</th>
<th>Degree or License (MD, RN, PA, none, etc)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Address (Please check one: ___ Home ___ Work)</th>
<th>Institution or Organization</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Address 2nd Line</th>
<th>Telephone ( ___Home ___Work)</th>
<th>Facsimile</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>City</th>
<th>State/Province</th>
<th>E-mail address to receive CME certificate ( ___Home ___Work)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The amount of time (in hours) I spent on reading the article, reviewing the references, reflecting on how the information might be applied to the practice, and taking the posttest was: 

☐ ≤ 1 ☐ 1.5 ☐ 2 ☐ 3 ☐ other _____

**Evaluation**

Please complete the following evaluation form for the Topics in Antiviral Medicine article for which you are currently claiming CME credit:

<table>
<thead>
<tr>
<th>Excellent</th>
<th>Very Good</th>
<th>Good</th>
<th>Fair</th>
<th>Poor</th>
</tr>
</thead>
<tbody>
<tr>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
<td>☐</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Content and presentation of article</th>
<th>☐</th>
<th>☐</th>
<th>☐</th>
<th>☐</th>
<th>☐</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Value in fulfilling learning objectives</th>
<th>☐</th>
<th>☐</th>
<th>☐</th>
<th>☐</th>
<th>☐</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Value to your practice/responsibility</th>
<th>☐</th>
<th>☐</th>
<th>☐</th>
<th>☐</th>
<th>☐</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Freedom from commercial bias</th>
<th>☐</th>
<th>☐</th>
<th>☐</th>
<th>☐</th>
<th>☐</th>
</tr>
</thead>
</table>

Please list 3 specific measurable changes you will make in your practice based on the information presented in the article:

1. ____________________________________________
2. ____________________________________________
3. ____________________________________________

Which parts of this journal-based CME activity could have been improved?

________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________

Other comments (please feel free to comment on any aspect of Topics in Antiviral Medicine):

________________________________________________________________________________________________________________________
____________________________________________________________________________________________________________________

Fax or mail this page along with the completed posttest to:
IAS–USA
425 California Street, Suite 1450
San Francisco, CA 94104-2120
Fax: (415) 544-9401